Skip to main content

Table 2 Rates of patient sustained virological responses and adherence to DAA treatments

From: Evaluation of pharmaceutical intervention in direct-acting antiviral agents for hepatitis C virus infected patients in an ambulatory setting: a retrospective analysis

Outcomes DCV+ASV
(n = 110)
SOF/LDV
(n = 184)
OBV/PTV/r
(n = 10)
EBR+GZR
(n = 11)
SOF+RBV
(n = 85)
OBV/PTV/r
+RBV (n = 1)
TOTAL
(n = 401)
Adherence
100%, n (%) 84 (76.4%) 170 (92.4%) 10 (100%) 10 (90.9%) 65 (76.5%) 0 (0%) 339 (84.5%)
≥95%, n (%) 109 (99.1%) 182 (98.9%) 10 (100%) 10 (90.9%) 85 (100%) 1 (100%) 397 (99.0%)
90–94%, n (%) 0 (0%) 1 (0.5%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (0.2%)
<90%, n (%) 1 (0.9%) 1 (0.5%) 0 (0%) 1 (9.1%) 0 (0%) 0 (0%) 3 (0.7%)
Completion the treatments, n (%) 101 180 9 10 85 1 386
Achieved SVR12, n (%) a 176/177 (99.4%) 10/10 (100%) 2/2 (100%) 77/77 (100%) 0/0 (0%) 265/266 (99.6%)
Achieved SVR24, n (%) a 93/99 (93.9%) 93/99 (93.9%)
  1. aPatients were excluded if they have not reached12 or 24 weeks after the completion of treatment
  2. DCV Daclatasvir, ASV Asunaprevir, SOF Sofosbuvir, RBV Ribavirin, LDV Ledipasvir, OBV Ombitasvir, PTV Paritaprevir, r Ritonavir, EBR Elbasvir and GZR Grazoprevir